Regeneration with Induced pluripotent stem cell Banking
Regeneration with Induced pluripotent stem cell Banking
Induced pluripotent stem cells (iPSCs) are reprogrammed somatic cells (generally skin or blood cells) that have been reprogrammed back into an embryonic cell-like state by introducing special factors. iPSCs can be differentiated to any type of somatic cells such as neurons or heart cells.
iPSC technology was first developed by Dr. Shinya Yamanaka, who received the Nobel Prize in Physiology or Medicine in 2012 for the discovery.
iPSCs have three main features that make them suitable for regenerative medicine, cell therapy, and drug discovery.
Why iPSC?
- Ability to be produced from mature cells in the body. iPSCs can be made by introducing special factors into various types of cells such as blood, skin, and hair cells and culturing them. At [ We] , we will make iPSCs from blood cells.
- Ability to transform into cells of various tissues and organs. A major feature of iPSCs is that they have “pluripotency”. Pluripotency means being able to become cells of various types, such as neurons and cardiomyocytes.
- Ability to proliferate almost indefinitely. Since iPSCs can divide and proliferate quite well, they can be cultured and expanded to obtain the number of cells necessary for cell transplantation and research with ease.
Our Technology
generate clinical-grade iPSCs for your personal regenerative medicine and cell therapy use. Regenerative medicine is a treatment that restores the function of a part of a body that has been lost due to injury or illness. iPSCs can theoretically be made from anyone’s cells and can be converted into a variety of cells that make up the body. iPSCs are also considered an ideal source for cell transplantation therapy because they can be expanded almost indefinitely. Since large numbers of cells are required for cell transplantation; this feature is crucial.
The New Frontier
Since Professor Shinya Yamanaka announced the successful generation of human iPSCs in 2007, various studies have been conducted for clinical applications globally. Examples of diseases for which clinical research has already begun including age-related macular degeneration, Parkinson’s disease, severe ischemic cardiomyopathy, and spinal cord injury. In addition, research is being conducted on application to diabetes, corneal disease, cerebral infarction, and liver and kidney diseases, among many others.
Regenerative medicine and iPSC technology are relatively new industry, and it is growing quickly. iPSCs generated from your blood can be used to manufacture many different types of cells including, but not limited to, cardiomyocytes, neurons, neuronal progenitor cells, fibroblasts, keratinocytes, mesenchymal stem cells, hepatocytes, pancreatic cells, T cells, B cells, NK cells, myeloid-derived precursor cells, hematopoietic stem cells, alveolar cells, bronchial epithelial cells, etc.
iPSC-derived cell therapy may be used to treat a variety of diseases, including but not limited to, Parkinson’s, amyotrophic lateral sclerosis (ALS), muscular dystrophy, spinal cord injury, stroke, coronary artery disease, heart disease, age-related macular degeneration, diabetes, metabolic liver disease, multiple myeloma, solid tumors, leukemia, hematologic malignancies, thalassemia, endometriosis, cystic fibrosis, asthma, etc. At this time, there are no FDA or PMDA approved iPSC-derived cell therapies for any diseases. Even when there are approved iPSC-derived cell therapies, there may not be an autologous iPSC-derived cell therapy, and your personal iPSCs may not be used.
